Cargando…

Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors

Pediatric brain tumors have surpassed leukemia as the leading cause of cancer-related death in children. Several landmark studies from the last two decades have shown that many pediatric brain tumors are driven by epigenetic dysregulation within specific developmental contexts. One of the major dete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Groves, Andrew, Clymer, Jessica, Filbin, Mariella G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227239/ https://www.ncbi.nlm.nih.gov/pubmed/35745584 http://dx.doi.org/10.3390/ph15060665

Ejemplares similares

Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
por: Sun, Hui-Yan, et al.
Publicado: (2022)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
por: Nguyen, Martin V., et al.
Publicado: (2020)

Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors
por: Wadhwa, Elizabeth, et al.
Publicado: (2016)

Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes
por: Li, Feng, et al.
Publicado: (2020)

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
por: Kulikowski, Ewelina, et al.
Publicado: (2020)

Bioactivation of Isoxazole-Containing Bromodomain and Extra-Terminal Domain (BET) Inhibitors
por: Flynn, Noah R., et al.
Publicado: (2021)

Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi)
por: Bian, Benjamin, et al.
Publicado: (2019)

Selective bromodomain and extra-terminal bromodomain inhibitor inactivates macrophages and hepatic stellate cells to inhibit liver inflammation and fibrosis
por: Fu, Rong, et al.
Publicado: (2022)

Discovery of Benzo[d]imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
por: Cipriano, Alessandra, et al.
Publicado: (2022)

The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors
por: Wong, C, et al.
Publicado: (2014)

Anticancer Effects of I-BET151, an Inhibitor of Bromodomain and Extra-Terminal Domain Proteins
por: Lai, Jiacheng, et al.
Publicado: (2021)

Molecular Dynamic Simulations of Bromodomain and Extra-Terminal Protein 4 Bonded to Potent Inhibitors
por: Chen, Siao, et al.
Publicado: (2021)

Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases
por: Wu, Dayu, et al.
Publicado: (2022)

Bromodomain and Extra-Terminal Proteins in Brain Physiology and Pathology: BET-ing on Epigenetic Regulation
por: Martella, Noemi, et al.
Publicado: (2023)

Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members
por: Malik, Nazma, et al.
Publicado: (2015)

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
por: Alqahtani, Ali, et al.
Publicado: (2019)

Succinate dehydrogenase B-deficient cancer cells are highly sensitive to bromodomain and extra-terminal inhibitors
por: Kitazawa, Satoshi, et al.
Publicado: (2017)

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
por: Trivedi, Archit, et al.
Publicado: (2020)

Prognostic role of overexpressed Bromodomain and extra-terminal family in ovarian cancer
por: Chetry, Mandika, et al.
Publicado: (2022)

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
por: Sun, Yanli, et al.
Publicado: (2021)

Muscle hypertrophy in hypoxia with inflammation is controlled by bromodomain and extra-terminal domain proteins
por: Chabert, Clovis, et al.
Publicado: (2017)

Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?
por: Groves, Ian J., et al.
Publicado: (2020)

Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function
por: Pinz, Sophia, et al.
Publicado: (2015)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
por: Taniguchi, Yasushi
Publicado: (2016)

Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease
por: Manni, Michelle L., et al.
Publicado: (2017)

Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia
por: Carrà, Giovanna, et al.
Publicado: (2019)

Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN
por: Shi, Xiyao, et al.
Publicado: (2022)

Regulation of inflammatory genes in decidual cells: Involvement of the bromodomain and extra-terminal family proteins
por: Ajgaonkar, Sandeep, et al.
Publicado: (2023)

Bromodomain and Extra Terminal (BET) Inhibitor Suppresses Macrophage-Driven Steroid-Resistant Exacerbations of Airway Hyper-Responsiveness and Inflammation
por: Nguyen, Thi Hiep, et al.
Publicado: (2016)

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors
por: Piha-Paul, Sarina A, et al.
Publicado: (2019)

A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid‐targeted bromodomain and extra‐terminal domain inhibitor
por: Brown, Jack A., et al.
Publicado: (2021)

Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods
por: Gonzalez Castro, L Nicolas, et al.
Publicado: (2022)

Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis
por: Zhang, Meng-Yi, et al.
Publicado: (2020)

Erratum to: Characterizing the biology of primary brain tumors and their microenvironment via single-cell profiling methods
por: Gonzalez Castro, L Nicolas, et al.
Publicado: (2022)

Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
por: Zhou, Bing, et al.
Publicado: (2017)

Bromodomain and extra-terminal (BET) proteins target Moloney murine leukemia virus integration to transcription start sites
por: De Riick, Jan, et al.
Publicado: (2013)

77232 The role of the bromodomain and extra-terminal motif (BET) family of proteins in head and neck cancer tumorigenic phenotype
por: Sample, Reilly A., et al.
Publicado: (2021)

DIPG-53. LSD1 DEGRADATION SYNERGIZES WITH HDAC INHIBITION IN PEDIATRIC H3K27M DIFFUSE MIDLINE GLIOMA
por: Haase, Rebecca, et al.
Publicado: (2023)

Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment
por: Huang, Xu-Sheng, et al.
Publicado: (2022)

Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma
por: Meng, Yuting, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mo8l5prgbs82l21tmtbdg3t7rd